Sabrina Poulos is a partner in Goodwin’s Life Sciences group. She has been a practicing patent attorney for 15 years. She focuses on collaborating with management teams to craft and execute pragmatic, company-focused IP strategies specific to each stage of a company’s life, including creation, pre-clinical, clinical, venture investment, M&A/IPO exits, and commercialization. Sabrina represents growth-stage therapeutics companies whose technologies span the breadth of the life sciences, including antibodies, cell therapies, gene therapies, peptide-based therapies, genetic engineering, oncolytic viruses, small molecules, and RNA-based therapeutics.

Ms. Poulos represents investors in IP diligence matters and company creation, focusing on analyzing IP portfolios and creating pragmatic solutions to optimize the IP portfolio in order to maximize the return on an investment.

Areas of Practice
业务范围
Domaines D’Expertise
TÄTIGKEITSFELDER

Experience

工作经历

EXPÉRIENCE

ERFAHRUNG

Biologics

  • Advised Abexxa Therapeutics (antibodies) on all IP matters, including the acquisition by Boehringer Ingelheim
  • Advise Boehringer Ingelheim on all IP matters relating to the Abexxa portfolio
  • Advise BIOMILQ (cellular agriculture/synthetic biology) on all IP matters, including their $21 million Series A Financing
  • Advise Exavir Therapeutics (CRISPR) on all IP matters
  • Advised Excision Bio (CRISPR) on all IP matters*
  • Advise Hemab (antibodies) on all IP matters
  • Advised Mirna Therapeutics (microRNA) on all IP matters, including the $43.75 million IPO and acquisition by Synlogic*
  • Advise Nogra (ASOs) on all ASO IP matters
  • Advise Nuvig Therapeutics (Fc therapeutics) on all IP matters, including the $47 million Series A financing
  • Advise OncoResponse (antibodies; Phase I clinical trials) on all IP matters related to OR2805, including their $40 million Series B financing and $40 million Series C financing
  • Advised PDI Therapeutics (antibodies) on all IP matters, including $26 million Series A*
  • Advise Treos Bio (peptide-based immunotherapies; Phase II clinical trials) on all US IP matters
  • Advise Triumvira (T cell therapies; Phase I clinical trials) on all IP matters, including the $100 million Series A financing

Small Molecules

  • Advise Avelas Biosciences (targeted imaging agents; Phase II clinical trials) on all IP matters
  • Advise ENB Therapeutics (small molecules; Phase I clinical trials) on all IP matters
  • Advise Exavir (small molecules) on all IP matters
  • Advise Morphimmune (targeted effector molecules) on all IP matters, including licensing transactions and the $12 million Series A financing
  • Advised OncoNano Therapeutics (targeted effector molecules and imaging agents) on all IP matters*
  • Advised Pharmacyclics (small molecules) on all IP matters related to HDAC portfolio and its $21 billion acquisition by AbbVie*
  • Advise Redesign Science (small molecules) on all IP matters
  • Advise Savara Pharmaceuticals (small molecules; Phase III clinical trials) on all IP matters
  • Advise Sporos Bioventures (small molecules) on all IP matters
  • Advise Tvardi Therapeutics (small molecules; Phase II clinical trials) on all IP matters including the $74 million Series A financing

Venture Capital

  • Advise Artis Venture Partners on select IP matters, including the $70 million Series A financing of Delix Therapeutics
  • Advise Avalon Bioventures on select IP matters, including formation of Avelas Biosciences and PDI Therapeutics
  • Advise Illumina Ventures on select IP matters
  • Advise Redmile on select IP matters, including the $70 million Series B financing of Lycia Therapeutics
  • Advise Research Bridge Partners on all IP matters, including formation of MorphImmune, Novosteo, and Tuebor Energy
  • Advise Sporos Bioventures on select IP matters, including the $14.5 million Series A financing of Asylia Therapeutics and the $15.5 million Series A financing of Stellanova Therapeutics

IPOs, M&As, and Licensing Transactions

  • Amylyx Pharmaceuticals in its $190 million IPO
  • Atsena Therapeutics in its license negotiations with the University of Florida*
  • Lumena Pharmaceuticals in its $260 million acquisition by Shire*
  • Seragon Therapeutics in its $1.7 billion acquisition by Roche/Genentech*
  • Special Committee of the Board of Directors of NantKwest in the merger of NantKwest and ImmunityBio

Medical Device/Software

  • Advised Alleviant Medical (interatrial shunt) on all IP matters*
  • Advised Genetesis (software/imaging device) on all IP matters, including $4.5 million Series A financing and $9.2 million Series B financing*
  • Advised IntuiTap Medical (image guided spinal tap device) on all IP matters*
  • Advised Tearlab (diagnostic device) on all IP matters*

*Denotes experience prior to joining Goodwin.

Professional Experience

Ms. Poulos began practicing in 2007 and was a partner at Wilson Sonsini in San Francisco prior to moving to Goodwin Procter.

Prior to law school, she spent three years engineering knock-out mice as a research associate at Lexicon Genetics, now Lexicon Pharmaceuticals.

Recognition

Ms. Poulos was a 2021 recommended lawyer for Patents and Healthcare by The Legal 500.

In The News

相关新闻

ACTUALITÉS

MELDUNGEN

Credentials

专业资格

RÉFÉRENCES

WERDEGANG

Education

J.D., 2007
University of San Diego School of Law
B.S., Biology, 2001
University of North Carolina, Chapel Hill

Admissions

Bar

California
Texas
U.S. Patent and Trademark Office (USPTO)
Profile Image
Get In Touch
联系我们
NOUS CONTACTER
Kontakt
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
搜寻其他律师
Recherche par Pratique
ANWALTSSUCHE